{{Rsnum
|rsid=10423928
|Gene=GIPR
|Chromosome=19
|position=45679046
|Orientation=plus
|GMAF=0.1928
|Assembly=GRCh38
|GenomeBuild=38.1
|dbSNPBuild=141
|geno1=(A;A)
|geno2=(A;T)
|geno3=(T;T)
|Gene_s=GIPR
}}{{ population diversity
| geno1=(A;A)
| geno2=(A;T)
| geno3=(T;T)
| CEU | 5.3 | 24.6 | 70.2
| HCB | 7.0 | 25.6 | 67.4
| JPT | 0.0 | 41.5 | 58.5
| YRI | 0.0 | 22.0 | 78.0
| ASW | 0.0 | 0.0 | 0.0
| CHB | 7.0 | 25.6 | 67.4
| CHD | 0.0 | 0.0 | 0.0
| GIH | 0.0 | 0.0 | 0.0
| LWK | 0.0 | 0.0 | 0.0
| MEX | 0.0 | 0.0 | 0.0
| MKK | 0.0 | 0.0 | 0.0
| TSI | 0.0 | 0.0 | 0.0
| HapMapRevision=28
}}{{PMID Auto GWAS
|PMID=20081857
|Trait=Two-hour glucose challenge
|Title=Genetic variation in GIPR influences the glucose and insulin responses to an oral glucose challenge
|RiskAllele=A
|Pval=3E-12
|OR=0.09
|ORtxt=[0.07-0.11] mmol/L increase
|OA=1
}}

{{PharmGKB
|RSID=rs10423928
|Name_s=
|Gene_s=GIPR
|Feature=
|Evidence=PubMed ID:20081857
|Annotation=Risk or phenotype-associated allele: A . Phenotype 1: In a meta-analysis of nine genome-wide association studies (n = 15,234 nondiabetic individuals) and a follow-up of 29 independent loci (n = 6,958-30,620), this SNP was found to be associated with 2-h glucose level (a clinical measure of glucose tolerance). Effect (s.e.m.) = 0.09(0.01) mmol/l per A allele. Study size/population/ethnicity: 15,234 plus 6,958-30,620 nondiabetic individuals of European descent. Significance metric(s): p = 1.98 x 10(-15). Phenotype 2: This SNP was also found to be associated with decreased insulin secretion. Effect(BMI adjusted) (s.e.m.) on Insulinogenic index = - 0.076(0.009) microUnits/mmol per A allele. Study size/population/ethnicity: > 22,000 nondiabetic individuals of European descent. Significance metric(s): p(BMI-adj) = 1.00x 10(-17). Phenotype 3: This SNP was also found to be associated with AUC insulin/glucose (another measure of insulin response during an oral glucose tolerance test). Effect(BMI adjusted) (s.e.m.) on AUC for insulin/glucose = - 0.051(0.007) pmol/mmol per A allele. Study size/population/ethnicity: 22,209 nondiabetic individuals of European descent. Significance metric(s): p(BMI adj) = 9.50 x 10(-17). Type of association: CO;GN.
|Drugs=
|Drug Classes=
|Diseases=Diabetes Mellitus, Type 2
|Curation Level=Curated
|PharmGKB Accession ID=PA165281980
}}

{{omim
|id=137241
|rsnum=10423928
}}

{{omim
|id=613460
|rsnum=10423928
}}

{{PMID Auto
|PMID=21747410
|Title=Association between the GIPR gene and the insulin level after glucose loading in schizophrenia patients treated with olanzapine.
}}

{{PMID|21810601|OA=1
}} Pleiotropic effects of GIP on islet function involve osteopontin.

{{PMID|22399504}} Genetic variation in the glucose-dependent insulinotropic polypeptide receptor modifies the association between carbohydrate and fat intake and risk of type 2 diabetes in the Malmo Diet and Cancer cohort.

{{GET Evidence
|impact=pharmacogenetic
|qualified_impact=Insufficiently evaluated pharmacogenetic
|inheritance=unknown
|quality_scores=Array
|dbsnp_id=rs10423928
|overall_frequency_n=26
|overall_frequency_d=126
|overall_frequency=0.206349
|n_genomes=20
|n_genomes_annotated=0
|n_haplomes=22
|n_articles=1
|n_articles_annotated=0
|in_pharmgkb=Y
|autoscore=1
|webscore=N
}}

{{PMID Auto GWAS
  |PMID=23563607
  |Trait=Obesity
  |Title=Genome-wide meta-analysis identifies 11 new loci for anthropometric traits and provides insights into genetic architecture.
  |RiskAllele=T
  |Pval=4E-13
  |OR=1.16
  |ORtxt=[NR]
  |OA=1
}}

{{PMID Auto
|PMID=23349498
|Title=Link between GIP and osteopontin in adipose tissue and insulin resistance.
}}

{{on chip | 23andMe v3}}
{{on chip | 23andMe v4}}